Aminoacids in the synthesis of heterocyclic systems: The synthesis of triazinoquinazolinones, triazepinoquinazolinones and triazocinoquinazolinones of potential biological interest

Article abstract of DOI:10.3390/60300267

A number of novel triazinoquinazolinones (5b,c and 8), triazepinoquinazolinones(5a, 6b, 7 and 9) and triazocinoquinazolinones (6a and 10) were obtained via nucleophilic interaction of 3-aminoquinazolinone derivatives 3 with different reagents.

Full text of DOI:10.3390/60300267

Molecules 2001, 6, 267-278
molecules
ISSN 1420-3049
http://www.mdpi.org
Aminoacids in the Synthesis of Heterocyclic Systems: The
Synthesis of Triazinoquinazolinones, Triazepinoquinazolinones
and Triazocinoquinazolinones of Potential Biological Interest
A.M.Sh.El-Sharief1,a, Y.A.Ammar1,*, M.A.Zahran1, A.H.Ali1 and M.S.A.El-Gaby2,b
1Department of Chemistry, Faculty of Science, Al-Azhar University, Nasr-City 11884, Cairo, Egypt.
aE-mail: ahmed_shab@hotmail.com; Fax: 002(02)2629356
2Department of Chemistry, Faculty of Science, Al-Azhar University at Assiut, Assiut 71524 Egypt.
bE-mail: m_elgaby@hotmail.com, Fax: +20 88 325436
*Author to whom correspondence should be addressed; E-mail: yossry@yahoo.com
Received: 5 April 2000; in revised form 29 August 2000 / Accepted: 1 February 2001 / Published: 28
February 2001
Abstract: A number of novel triazinoquinazolinones (5b,c and 8), triazepinoquinazoli-
nones(5a, 6b, 7 and 9) and triazocinoquinazolinones (6a and 10) were obtained via
nucleophilic interaction of 3-aminoquinazolinone derivatives 3 with different reagents.
Keywords: Triazinoquinazolinones, triazepinoquinazolinones, triazocinoquinazolinones,
biological activity
Introduction
Varied biological activities have been attributed to quinazoline compounds, including analgesic,
antiinflammatory, antipyretic [1-3], antimicrobial [4], anticonvulsant [5], fungicidal [6], anti-
depressant and other central nervous system affecting activities [7]. The use of aminoacids as starting
materials for the design and synthesis of new quinazoline compounds with the aim of preparing
potent biologically active compounds is a subject of recent interest [8-11]. Now we report a facile
synthesis of several heterocyclic compounds containing six, seven and eight membered rings fused to
a quinazoline moiety starting from amino acids.

Molecules 2001, 6
268
Results and Discussion.
Synthesis and characterization
The starting materials 1a-f were prepared via reaction of the appropriate sulfonyl chloride
derivatives with amino acids in the presence of 10 % sodium hydroxide solution, followed by
acidification [12]. The amides 2a-f have been prepared by condensation of the corresponding 1a-f
with methyl anthranilate in presence of PCl3. 3-Aminoquinazolinones 3a-f were obtained by
refluxing compounds 2a-f with hydrazine hydrate in n-butanol (Scheme 1). Compounds 2a-f and 3a-
f have been fully characterized by their analytical and spectral data. For example, the IR spectrum of
compound 3e showed the presence of NH, NH2, CH-aliphatic, C=O and S=O functional groups. Also,
1
the H-NMR spectrum of compound 3e exhibited signals in the range of 0.85-0.92; 1.88; 2.15-2.24;
2.50-2.51; 5.51; 6.82-8.02; 10.6 ppm due to 2CH3 (d); CH3 (s); CH (m); CH (d); NH2 (s); Ar-H’s (m)
and SO2NH (s) respectively. The mass spectrum of compound 3c showed a molecular ion peak at m/z
434 (1.01%) which underwent fragmentation to give the well established fragment at m/z 91 (100%;
base peak; see Scheme 2).
Scheme 1
R
R
ArSO2NH(CH)nCOOH
1a-f
(i) NaOH
(ii) HCl
ArSO2Cl
+ NH2(CH)nCOOH
COOCH3
NH2
O
N
N
NH2
COOCH3
N2H4.H2O
(CH)nNHSO2Ar
R
N C (CH)nNHSO2Ar
H
R
O
3a-f
2a-f
R=H
Ar=C6H5
n=1
1,2,3a
Ar=p-CH3-C6H4
Ar= p-CH3-C6H4
Ar= p-CH3-C6H4
Ar= p-CH3-C6H4
Ar= p-CH3-C6H4
R=C6H5
n=1
n=1
n=2
n=1
n=1
b
c
d
e
f
R=CH2C6H5
R=H
R=CH(CH3)2
R=CH2CH(CH3)2

Molecules 2001, 6
269
Scheme 2: Proposed fragmentation pattern of compound 3c
O
+
.
H2N
N
H
SO2HN
Ph
H3C
SO2
N
A
m/z 434
(1%)
+
H3C
H3C
SO2NH
m/z 170
.
- CH2Ph
O
+
(17 %)
.
O
N
+
H2N
N
H2N
N
.
HN
N
SO2NH
SO2HN
H3C
H
H
Ph
m/z 343
(73%)
m/z 279
(7%)
+
.
H3C
.
.
NHSO2
CH3
-NH2
m/z 91
(100%; base peak)
O
N
O
N
+
+
.
.
H2N
.
.
.
N
H
N
H
-H
m/z 172
(3%)
- CH3
- CH
m/z 158
(2%)
HN
Ph
m/z 76
(63%)
m/z 173
(1%)
m/z 263
(9%)
.
- NH2
-CO
m/z 157
(2%)
+
.
N
H
HN
Ph
N
m/z 235
(3%)
3-Aminoquinazolinone derivatives 3d,e were used as a precursors for further cyclizations with the
purpose of synthesizing several heterocyclic compounds fused to the quinazoline moiety. Thus,
condensation of 3e with p-chlorobenzaldehyde in acetic acid furnished the corresponding Schiff’s
base 4. The structure of compound 4 was deduced from elemental analyses and spectral data. The IR
spectrum showed the absence of the NH2 group present in the parent compound and the presence of a
C=N group. On the other hand, refluxing compounds 3d,e with p-fluoro, p-chloro and p-methoxy-
benzaldehydes in DMF yielded the novel heterocyclic compounds 5a-c. Formation of 5 from the
reaction of 3 and an aldehyde is assumed to proceed in three steps. First, condensation of 3 and
aldehyde to yield Schiff’s bases 4; second, nucleophilic addition of NHSO2 to the activated C=N
bond to form intermediate (A) followed by the third step, elimination of sulphinic acid to furnish 5,
Scheme 3.

Molecules 2001, 6
270
Scheme 3
O
N
O
N
N
NH
CHAr`
2
Ar`CHO
AcOH
N
N
(CH) NHSO Ar
(CH) NHSO Ar
n
2
n
2
R
R
4
3
DMF
Ar`CHO/
DMF
O
N
O
N
H
H
N
N
H
Ar`
Ar`
-ArSO H
N
N
2
N
n
N
n
SO Ar
2
(CH)
R
(CH)
R
5a-d
A
n= 1, Ar= p-CH3-C6H4
R= CH(CH3)2
R= H
Ar`= p-Cl-C6H4
Ar`= p-Cl-C6H4
4
n= 2
n= 1
5a
R= CH(CH3)2 Ar`= p-F-C6H4
5b
5c
5d
R= CH(CH3)2
R= CH(CH3)2
Ar`= p-MeO-C6H4 n= 1
Ar`= p-Cl-C6H4
n= 1
Naphtho[2`,3`:3,4]-[1,2,5]triazocino[8,1-b]quinazolinone (6a) and naphtho[2`,3`:3,4]-[1,2,5]-
triazepino[7,1-b]quinazolinone (6b) were obtained by refluxing compounds 3d and 3e, respectively,
with 2,3-dichloro-1,4-naphthoquinone in DMF. This reaction takes place via loss of two HCl
molecules followed by elimination of toluenesulphinic acid.
Also, the 1,2,4-triazepino[7,1-b]quinazolinone 7 and 1,2,4-triazino[6,1-b]quinazolinone 8 were
isolated when compounds 3d and 3e were refluxed with bis[(methylsulfanyl)methylidene)-
malononitrile in DMF. The formation of the later compound proceeds via elimination of two methyl
mercaptan molecules followed by elimination of toluenesulphinic acid, Scheme 4.
As an extension of this work, when compound 3d was allowed to react with Cl(CH2)nCOOEt
system (n=0,1) in DMF and under reflux conditions, the triazepinoquinazolinone 9 and triazocino-
quinazolinone 10 were isolated, respectively. The postulated mechanism for this reaction involves the
initial attack by the chloroester followed then by a sequential elimination of ethanol and then
toluenesulphinic acid, which is a good leaving group, to give the intermediate (C) which is finally
alkylated, Scheme 5.

Molecules 2001, 6
271
Scheme 4
O
Cl
Cl
H
O
N
N
O
N
..
O
-2HCl
n(HC)
N
O
Ar
R
SO2
B
H
-ArSO2
O
N
O
N
N
3d,e
n(HC)
N
O
R
6a; R= H
b; R= CH(CH3 2
n=2
) n=1
NC
SMe
CN
O
H
C
C
N
N
CN
NC
SMe
N
-2 MeSH
N
Ar
SO2
(CH)n
R
R=H, n=2
) , n=1
R= CH(CH3 2
O
N
N
CN
CN
O
N
CN
CN
H
H
N
N
N
N
N
7
8

Molecules 2001, 6
272
Scheme 5
O
H
N
N
O
Cl(CH2)n.COOEt
3d
N
n=0,1
- HCl, C2H5OH
- HSO2Ar
N
H
c
+ Cl(CH2)nCOOEt
-HCl
n=1
n=0
O
N
O
N
H
H
N
O
COOEt
N
O
N
N
N
N
COOEt
10
9
Biological Activity
Antimicrobial activities
Compounds 2b,d,e, 3a,d,e,f, 9 and 10 were tested for their antimicrobial activity by the filter
paper disc method [13] using the gram positive bacteria Staphlococcus aureus (NCTC-7447) and
Bacillus cerus (ATCC-14579) and the gram negative bacteria Serratia marcesens (IMRU-70) and
Proteus merabitis (NCTC-289). The results of antimicrobial activity tests are summarized in Table 1.
Table 1: Antimicrobial screen of the newly synthesized compounds
Gram positive
Gram negative
Compd.
No.
Staphlococcus aureus Bacillus cereus Serratia marcesens
Proteus merabitis
(NCTC-7447)
(ATCC-14579)
(IMRU-70)
(NTC-289)
++
2b
2d
2e
3a
3d
3e
3f
++
+
++
++
++
++
++
++
++
++
++
++
++
++
++
++
+++
+++
++
++
++
+++
+++
+++
++
++
+++
+++
+++
++
+++
+++
++
9
++
10
++

Molecules 2001, 6
273
Most of the synthesized compounds were found to possess various antimicrobial activities
towards all the microorganisms used with minimal inhibitory concentration (MIC). The N-amino
compound 3d was found to possess antimicrobial activity against Bacillus cereus (ATCC-14579),
compound 3e containing the N-amino moiety possesses a high antimicrobial activity against
Staphlococcus aureus (NCTC-7447), Bacillus cereus (ATCC-14579) and Proteus merabitis (NTC-
289) and the N-amino compound 3f possesses antimicrobial activity towards Staphlococcuss aureus
(NCTC-7447), Serratia marcesens (IMRU-70) and Proteus merabitis (NTC-289). Also, compound 9,
containing the triazepinoquinazolinone moiety, was found to possess the highest antimicrobial
activity towards Staphlococcus aureus (NCTC-7447), Serratia marcesens (IMRU-70) and Proteus
merabitis (NTC-289).
Antifungal activities
The selected compounds were also tested for their antifungal activity using Aspergillus ochraceus
Wilhelm (AUCC-230) and Penicillium chrysogenum Thom (AUCC-530) (Table 2). Some of the
synthesized compounds were found to possess antifungal activities towards all the microorganisms
used with minimal inhibitory concentration (MIC). The amide 2d possesses a high antifungal activity
towards Aspergillus ochraceus Wilhelm (AUCC-230). Also compound 3d which contain the N-amino
moiety was found to possess the highest antifungal activity towards Penicillium chrysogenum Thom
(AUCC-530). On the other hand the triazepinoquinazolinone 9 was found to possess antifungal
activity against Penicillium chrysogenum Thom (AUCC-530).
Table 2: Antifungal activity of the synthesized compounds
Aspergillus ochraceus Wilhelm Penicillium chrysogenum Thom
Compd.No.
(AUCC-230)
(AUCC-530)
2b
2d
2e
3a
3d
3e
3f
++
+++
+
++
++
++
R
R
++
++
++
++
R
+++
++
++
+++
+
9
10
Key to the results: Inhibition zones were measured in mm. The concentration used was
4x10-5M. Control discs were done using dimethylformamide (DMF) and no inhibition
zones were observed. Results are reported as (R) resistant, (+) moderately sensitive
giving a 5 mm inhibition zone; (++) sensitive giving a 14 mm inhibition zone; (+++) very
sensitive giving a 20 mm inhibition zone.

Molecules 2001, 6
Experimental
General
274
Melting points were taken on a STUART apparatus and are uncorrected. The IR spectra (KBr
disks) were measured with a Jasco FT/IR 5300 spectrometer. The 1H-NMR spectra were obtained on
a Varian Gemini 200 instrument at 200 MHz using DMSO-d6 as a solvent and TMS as internal
standard. Mass spectra were performed by Shimadzu-GC MS QP 1000 EX using the direct inlet
system. Thin layer chromatography (TLC) was carried out on silica gel (MN-Kieselgel G., 0.2 mm
thickness) with ethylacetate:n-hexane (E/H) as the solvent and the plates were scanned under 254 nm
ultraviolet light. Microanalyses were performed by the Microanalytical Unit at Cairo University. All
the compounds gave satisfactory elemental analyses. Antimicrobial and antifungal activity tests were
carried out by the Microbiology Lab., Faculty of Science, Al-Azhar University, Cairo, Egypt.
General procedure for synthesis of tosyl aminoacids 1a-f.- The tosyl amino acid derivatives were
prepared according to McChesney et al [12] whereby the aminoacid (0.026 mol) was dissolved in 1N
sodium hydroxide (25 mL) and over a period of thirteen minutes a solution of p-toluenesulphonyl
chloride (0.027 mol) in ether (30 mL) was added in portions. The mixture was stirred at room
temperature for 3hrs. The excess p-toluenesulphonyl chloride was filtered off and the solution treated
with 2N HCl until acidic to Congo Red (pH 5). After cooling acidification caused the product to
precipitate. The crude product was filtered, washed with water and dried. The crude materials were
recrystallized to give 1a-f.
General procedure for synthesis of the amides 2a-f.- To a mixture of tosyl aminoacid (0.01 mol) and
methyl anthranilate (0.01 mol) in xylene (20 mL), phosphorous trichloride (2-3 mL) was added. The
mixture was heated under reflux for 3-4 hrs. After cooling and addition of pet.ether (bp 40-60°C; 10
mL) the precipitate was filtered and washed with two 5 mL portions of pet.ether, dried and
recrystallized from the appropriate solvent to give 2a-f.
Methyl N-[phenylsulphonyl-glycyl]anthranilate (2a).- From phenylglycyl chloride as colourless
crystals (65%), m.p. 125oC; IR νmax/cm-1 (2NH), 1703 (ester CO), 1680 (CO).
Methyl N-[4'-methylphenylsulphonyl-2-phenylglycyl]anthranilate (2b).- From tosyl 2-phenylglycyl
acid chloride as colourless crystals (71%), m.p. 155oC; IR νmax/cm-1 3190 (2NH), 1700 (ester CO),
1681 (CO).
Methyl N-[4'-methylphenylsulphonyl-phenylalaninyl]anthranilate (2c).- From tosyl phenylalaninyl
acid chloride as colourless crystals (68%), m.p. 120oC; IR νmax/cm-1 3195 (2NH), 1715 (ester CO),
1662 (CO).

Molecules 2001, 6
275
Methyl N-[4'-methylphenylsulphonyl-β-alaninyl]anthranilate (2d).- From tosyl-β-alaninyl acid
chloride as colourless crystals (73%), m.p. 130oC; IR νmax/cm-1 3190 (2NH), 1695 (ester CO), 1660
(CO).
Methyl N-[4'-methylphenylsulphonyl-DL-valinyl]anthranilate (2e).- From tosyl-DL-valinyl acid
chloride as colourless crystals (75%), m.p. 170oC; IR νmax/cm-1 3220 (2NH), 1721 (ester CO), 1676
1
(CO); H-NMR δ 0.85-0.87 (d, 3H, isopropyl CH3), 0.90-0.93 (d, 3H, isopropyl CH3), 2.02-2.13 (m,
1H, CH), 2.37 (d, 1H, CH), 2.45 (s, 3H, CH3), 3.98 (s, 3H, OCH3), 7.26-8.55 (m, 8H, ArH’s), 11.12
ppm (s, 2H, 2NH).
Methyl N-[4'-methylphenylsulphonyl-DL-leucinyl]anthranilate (2f).- From tosyl-DL-leucine acid
chloride as colourless crystals (68%), m.p. 165oC; IR νmax/cm-1 3180 (2NH), 1698 (ester CO), 1663
(CO).
General procedure for synthesis of N-amino quinazolin-4(3H)-one derivatives (3a-f).- The
corresponding amide 2a-f (0.01 mol) and 95% hydrazine hydrate (0.05 mol) were dissolved in n-
butanol (30 mL) and refluxed for 6-8 hrs. Cooling in ice gave the crude product which was filtered
off and recrystallized to give compounds 3a-f.
3-Amino-2-(phenylsulphonamidomethyl)quinazolin-4(3H)-one (3a).- Colourless crystals (74%);
m.p. 180oC; IR νmax/cm-1 3320 (NH2), 3210 (NH), 3060 (CH-arom.), 2960 (CH-aliph.), 1660 (CO).
3-Amino-2-(1`(4-methylphenylsulphonyl)-1`-(phenyl)methyl]quinazolin-4(3H)-one (3b).- Colour-
less crystals (65%), m.p. 135oC; IR νmax/cm-1 3325 (NH2), 3298 (NH), 3060 (CH-arom.), 2910 (CH-
aliph.), 1669 (CO), 1598 (C=N).
3-Amino 2-[1`(4-methyl phenylsulphonamido)-1`-(benzyl)methyl]quinazo-line-4-(3H)-one (3c).-
Colourless crystals (68%), m.p. 170oC; IR νmax/cm-1 3316 (NH2), 3241 (NH), 3055 (CH-arom.), 2972
(CH-aliph.), 1667 (CO); MS (C23H22N4O3S): m/e 434 (M+, 1%), 343 (73.3%), 328 (10.6%), 235
(2.7%), 188 (4.6%), 172 (2.7%), 145 (4.2%), 91 (100%, base peak), 65 (22.6%).
3-Amino-2-[4-methyl phenylsulphonamidoethyl]quinazolin-4-(3H)-one (3d).- Colourless crystals
(70%), m.p. 185oC, IR νmax/cm-1 3322, 3294 (NH2), 3260 (NH), 1666 (CO.), 1614 (C=N).
3-Amino-2-[1`-(4-methylphenylsulphonamido)-1`-(iso-propyl)methyl]quinazolin-4-(3H)-one (3e).-
Colourless crystals (76%), m.p. 190oC; IR νmax/cm-1 3320, 3290 (NH2), 3250 (NH), 1665 (CO), 1611
(C=N); MS (C19H22N4O3S): m/e 387(M+1, 4.5%), 353 (5.6%), 343 (5%), 275 (11%), 226(39.6%),
1
185 (15.3%), 155 (51.6%), 91 (100%, base peak), 65 (32%); H-NMR δ 0.85-0.92 (d, 6H, 2CH3),
1.88 (s, 3H, CH3), 2.15-2.24 (m, 1H, CH), 2.50-2.51 (d, 1H, CH +DMSO), 5.51 (s, 2H, NH2;
exchangeable with D2O), 6.82-8.02 (m, 8H, Ar-H’s), 10.6 (s, 1H, NH; exchangeable with D2O).

Molecules 2001, 6
276
3-Amino 2-[1`-(4-methylphenylsulphonamido)-1`-(iso-butyl)methyl]quina-zolin-4-(3H)-one (3f).-
1
Colourless crystals (71%), m.p. 170oC; H-NMR δ 0.88-0.94 (d, 6H, 2CH3), 1.52-1.59 (t, 2H, CH2),
1.82-1.90 (m, 1H, CH), 2.50-2.52 (d, 1H, CH +DMSO), 5.57 (s, 2H, NH2; exchangeable with D2O),
6.86-8.04 (m, 8H, Ar-H’s), 10.2 (s, 1H, NH; exchangeable with D2O).
The Schiff’s base of 3-amino-2-[1`-(4-methyl phenyl sulphonamido)-1`-(iso-propyl)methyl]-
quinazolin-4-(3H)-one (4).- Prepared from 3e (0.01 mol) and 4-chlorobenzaldehyde (0.01 mol) in
acetic acid (20 mL). The mixture was refluxed for 4 hrs., cooled and colected by filteration as pale
brown crystals (69%); m.p. 160oC; IR νmax/cm-1 3220 (NH), 3050 (CH-arom.), 2985 (CH-aliph.),
1660 (CO).
General procedure for the synthesis of 5a-c.- Compounds 3d,e (0.01 mol) and the corresponding
aldehyde derivative (0.01 mol) in DMF (20 mL) containing 2 drops of triethylamine was refluxed for
6-8 hrs., after cooling and acidification with dil. HCl, a precipitate was formed, which was collected
by filtration, washed with water and recrystallized to give 5a-c.
2-(4-Chlorophenyl)-4,5,11-trihydro-1H[1,2,4]triazepino[7,1-b]quinazolin-11-one (5a).- Prepared
from 3d and 4-chlorobenzaldehyde as brown crystals (67%), m.p. 260oC; IR νmax/cm-1 3210 (NH),
1
1664 (CO), 1590 (C=N); H-NMR δ 4.23, 4.6 (2s, 4H, 2CH2), 7.2-8.4 (m, 8H, Ar-H’s), 9.2 (s, 1H,
NH; exchangeable with D2O).
2-(4-Fluorophenyl)-4-isopropyl-4,10-dihydro-1H[1,2,4]triazino[6,1-b]-quinazolin-10-one (5b).-
Prepared from 3e and 4-fluorobenzaldehyde as pale brown crystals (62%), m.p. 180oC; IR νmax/cm-1
3195 (NH), 2995, 2890 (CH-aliph), 1658 (CO).
2-(4-Methoxyphenyl-4-isopropyl-4,10-dihydro-1H-[1,2,4]triazino[6,1-b] quinazolin-10-one (5c).-
Prepared from 3e and 4-methoxybenzaldehyde as brown crystals (60%), m.p. 170oC; IR νmax/cm-1
3210 (NH), 2990, 2885 (CH-aliph.), 1665 (CO).
6,7,9,14,17-Pentahydronaphtho[2`,3`:3,4][1,2,5]triazocino[8,1-b]qinozolin-9,14,17-trione (6a).-
Prepared in a similar fashion as 6a from 3d and 2,3-dichloro-1,4-naphthoquinone as deep brown
crystals (63%), m.p. > 300oC; IR νmax/cm-1 3060 (CH-arom.), 1670, 1660 (3CO).
6-Isopropyl-6,8,13,16-tetrahydronaphtho[2`,3`:3,4][1,2,5]triazepino[7,1-b]-quinazolin-8,13,16
trione (6b).- Prepared from 3e (0.01 mol); 2,3-dichloro-1,4-naphthoquinone (0.01 mol) in DMF (20
mL) and TEA (0.05 mL), the reaction mixture was refluxed for 6 hrs., cooled and acidified with HCl,
the precipitate was filtered, washed with water and recrystallized to give 6a as dark brown crystals
(60%); m.p. > 300oC; MS (C22H16N4O3) m/e 384 (5.9%), 328 (8.1%), 278 (12.5%), 224 (14.8%), 183
(21.7%), 137 (24.3%)), 97 (100%), 1H-NMR δ 0.87-0.89 (dd, 3H, isopropyl CH3), 0.91-0.94 (dd, 3H,
isopropyl CH3), 2.04-2.15 (m, 1H, isopropyl CH), 7.02-8.34 (8H,m,Ar-H’s).

Molecules 2001, 6
277
2-[11-Oxo5,11-dihydro-1H-[1,2,4]triazepino[7,1-b]quinazolin-2-ylidine]-malononitrile (7).- From
3d and [bis(methylthio)methylene]malononitrile as yellow crystals (61%); m.p. 250oC; MS
(C14H8N6O) m/e 276 (3%), 229 (3.8%), 203 (26.3%), 186 (17.6%), 160 (77.4%), 91 (100%, base
peak), 65 (46.8%), 1H-NMR δ 4.3 (d, 2H, CH2), 4.5 (dd, 1H, CH), 7.2-8.3(m, 4H, Ar-H’s + 1H, NH;
exchangeable with D2O).
2[4-isopropyl-10-oxo-1,10-dihydro-[1,2,4]-triazino-[6,1-b]quinazolin-2-ylidine) malononitrile (8)
Prepared from 3e (0.01 mol), [bis(methylthio)methylene)malononitrile (0.02 mol) in DMF (20 mL)
and TEA (0.5 mL). The reaction mixture was refluxed for 5 hrs. until the odour of methyl mercaptan
disappeared. Cooling and acidification caused the precipitation of the product which was then
collected and recrystallized to give 7 as pale yellow crystals (66%), m.p. > 300oC; IR νmax/cm-1 3210
(NH), 2210 (2CN), 1659 (CO).
Ethyl 1-[11-oxo-5,11-dihydro-[1,2,4]triazepino[7,1-b]quinazolinyl]formate (9).- Prepared from 3d
(0.01 mol), ethyl chloroformate (0.03 mol) and TEA (0.5 mL) in DMF (20 mL). The mixture was
refluxed for 8 hrs., cooled and acidified with dil. HCl. The solid obtained was collected and
crystallized to give 9 as pale brown crystals (60%), m.p. 265oC; MS (C14H12N4O4) m/e 300 (M+1,
0.5%), 284 (2.9%), 256 (7%), 213 (4.9%), 185 (6.2%), 149 (16.6%), 129 (10.8%), 91 (22.3%), 65
(8%); 1H-NMR δ 1.28-1.33 (t, 3H, CH3), 4.23-4.30 (q, 2H, CH2), 4.41, 4.5 (2s, 2H, 2CH), 7.29-8.29
(m, 4H, Ar-H’s + 1H, NH; exchangeable with D2O).
Ethyl-1-[12-oxo-6,12-dihydro[1,2,5]triazocino[8,1-b]quinazolinyl]acetate (10).- Prepared like 9
from 3d and ethyl chloroacetate as pale brown crystals (63%), m.p. > 300oC, MS (C16H16N4O4) m/e
328 (0.5%), 299 (0.7%), 284 (0.8%), 256 (7.3%), 213 (4.3%), 185 (5.2%), 149 (15.8%), 69 (100%;
1
base peak); H-NMR δ 1.24-1.32 (t,3H, CH3 -ethyl), 1.80 (s, 2H, CH2), 4.09-4.15(q, 2H, CH2 ethyl),
7.2-8.3 (m, 4H, Ar-H’s + 2H, 2NH; exchangeable with D2O).
References
1. Daidone, G.; Maggio, B.; Raffa, D.; Plescia, S.; Bajardi, M. L.; Caruso, A.; Cuttuli, V. M. C. and
Amico-Roxas, M.: Eur. J. Med. Chem., 1994, 29, 707.
2. A.A.Bckhit and M.A.Khalil, Pharmazie, 1998, 53, 539.
3. Agarwal, R.; Singli, C.and Mishara, N.S.: Ind. Drugs, 1988, 25, 185.
4. Pramella, B.; Rajanarender, E.; Murty, A. K.: Ind. J. Heterocyclic Chem., 1992, 2, 115.
5. Shyimad, M.; Kalsi, R.; Dixit, K. S.and Barthwal, J. P.: Arzneim-Fosch. Drug Res., 1991, 41,
514.
6. Shakhidoyator, Kh. M.; Eripor, E. O.; Yun, L. M.; Yamankulov, M. Ya and Kadyrov, Ch. Sh.;
Fungitsidy, 1980, 66; Chem. Abstr.: 1981, 94, 192253.
7. Fetter, J.; Czuppon, T.; Hornyak, G. and Feller, A.: Tetrahedron, 1991, 47, 9393.
8. Kralj, L.; Hvala, A.; Sreto, J.; Golic, L. and Stanovik, B.: J. Heterocyclic Chem., 1997, 34, 247.

Molecules 2001, 6
278
9. Mohamed, Y. A.; El-Sharief, A. M. Sh.; Ammar, Y. A.; Amin, N. E. and Ghorab, M. M.: J. Serb.
Chem. Soc., 1989, 54, 179.
10. Ammar, Y. A.; El-Sharief, A. M. Sh.; Mohamed, Y. A. and Ahmed, H. A.: J. Serb. Chem. Soc.,
1987, 52, 633.
11. Hassanein, A. A.; Nassar, O. M.; Zahran, M. A. and Ali, A. H.: Al-Azhar Bull. Sci., 1997, 8, 417.
12. McChesney, E.W. and Kirkswann, W. M.: J. Am. Chem. Soc., 1937, 59, 1116.
13. Elslager, E.F.: Prog. Drug. Res., 1974, 18, 99.
Sample Availability: Samples are available from the authors.
© 2000 by MDPI (http://www.mdpi.org). Reproduction is permitted for noncommercial purposes